Current clinical management of CIDP with immunoglobulins in France: An expert opinion

Rev Neurol (Paris). 2023 Apr 3:S0035-3787(23)00892-5. doi: 10.1016/j.neurol.2023.03.010. Online ahead of print.ABSTRACTTreatment strategies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) must be adapted on a case-to-case basis. Validated and reproducible tools for monitoring treatment response are required at diagnosis, when initiating treatment and throughout follow-up. A task force of French neurologists, experts in neuromuscular disease reference centers, was assembled to provide expert advice on the management of typical CIDP with intravenous immunoglobulins (Ig), and to harmonize treatment practices in public and private hospitals. The task force also referred to the practical experience of treating CIDP with Ig at the diagnostic, induction and follow-up stages, including the assessment and management of Ig dependence, and following the recommendations of the French health agency.PMID:37019741 | DOI:10.1016/j.neurol.2023.03.010

Source: Revue Neurologique - April 5, 2023 Category: Neurology Authors: P Cintas F Bouhour C Cauquil M Masingue C Tard S Sacconi E Delmont A Choumert J-B Chanson M Michaud G Sol é J Cassereau J-B Noury G Nicolas R Bellance Y P éréon J-P Camdessanch é L Magy S Attarian French Neuromuscular diseases network (Filnemus) Source Type: research